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Stem cell therapy holds great promise for tissue regeneration and cancer treatment, although its 
efficacy is still inconclusive and requires further understanding and optimization of the procedures. 
Non‑invasive cell tracking can provide an important opportunity to monitor in vivo cell distribution 
in living subjects. Here, using a combination of positron emission tomography (PET) and in vitro 
2‑deoxy‑2‑[18F]fluoro‑D‑glucose ([18F]FDG) direct cell labelling, the feasibility of engrafted stem 
cell monitoring was tested in multiple animal species. Human mesenchymal stem cells (MSCs) were 
incubated with phosphate‑buffered saline containing [18F]FDG for in vitro cell radiolabelling. The 
pre‑labelled MSCs were administrated via peripheral vein in a mouse (n = 1), rats (n = 4), rabbits (n = 4) 
and non‑human primates (n = 3), via carotid artery in rats (n = 4) and non‑human primates (n = 3), and 
via intra‑myocardial injection in rats (n = 5). PET imaging was started 10 min after cell administration 
using a dedicated small animal PET system for a mouse and rats. A clinical PET system was used 
for the imaging of rabbits and non‑human primates. After MSC administration via peripheral vein, 
PET imaging revealed intense radiotracer signal from the lung in all tested animal species including 
mouse, rat, rabbit, and non‑human primate, suggesting administrated MSCs were trapped in the 
lung tissue. Furthermore, the distribution of the PET signal significantly differed based on the route 
of cell administration. Administration via carotid artery showed the highest activity in the head, and 
intra‑myocardial injection increased signal from the heart. In vitro [18F]FDG MSC pre‑labelling for 
PET imaging is feasible and allows non‑invasive visualization of initial cell distribution after different 
routes of cell administration in multiple animal models. Those results highlight the potential use of 
that imaging approach for the understanding and optimization of stem cell therapy in translational 
research.
In recent decades, stem cell therapy has gained broad interest due to its potential for tissue regenerative 
 medicine1,2. Multiple preclinical and clinical studies have shown promising positive effects of grafted stem cells 
on the repair and regeneration of various tissues, such as in stroke and myocardial  infarction3. Additionally, 
stem cells have been shown to migrate into tumours, making them potential vehicles for anticancer  therapy4–6.
In the clinical practice of cell therapy, one of the major technical issues is how to efficiently deliver the stem 
cells into the target tissues and the route of administration needs to be taken into special  consideration7,8. 
Intravenous cell administration is the easiest and relatively non-invasive route, allowing for repeated injection. 
However, such systemic administration may require a larger amount of total cell dose and needs sufficient and 
long-distance cell migration into the target area. Selective cell administration via an arterial blood vessel, perfus-
ing the target tissue, is minimally-invasive and would be expected to improve the efficacy of cell delivery. At the 
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same time, it carries risks of embolism and of poor delivery to hypoperfused areas. Finally, intra-tissue direct cell 
injection could further improve the number of delivered cells, even in hypo-perfused regions, while there may 
be spillover to nontarget organs and loss of cells due to mechanical alterations. Nevertheless, direct injection is 
an invasive procedure which may limit clinical application depending on the location of the target tissue. There 
is also a need for a better understanding of the dynamics of administered cells in vivo, as the efficacy of delivery 
and cell survival may vary depending on the types of stem cell and the target tissue/organ9.
Non-invasive imaging is a relevant tool for monitoring and optimizing the procedure of cell therapy in liv-
ing  subjects10–12. Radionuclide molecular imaging is a routinely available technology for the visualization of 
key molecular and cellular alterations in patients and animal models. Positron emission tomography (PET) can 
serve as a highly sensitive and quantitative approach for visualizing those molecular and cellular events. Meth-
ods utilizing PET technology to monitor stem cells have been  proposed13,14. For instance, Patrick et al. recently 
demonstrated the usefulness of [89Zr]Zr-oxine labelling and PET imaging for evaluating the biodistribution 
of novel, highly innovative cell  therapies15. Promising results have been also achieved with 3’-deoxy-3’-[18F]
fluorothymidine16. In vitro pre-labelling with the glucose analog 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG), 
followed by cell administration and PET imaging, however, is one of the simplest and well established approaches 
for monitoring stem cell distribution in living  organisms17,18, in particular as [18F]FDG is widely available at 
every PET facility with access to a  cyclotron19. We tested the feasibility to assess stem cell distribution in multiple 
animal species after different routes of administration using PET imaging.
Material and methods
All reagents were commercial products and used without further purification unless otherwise indicated. Animal 
studies were approved by the local institutional animal ethics committee (approved number 18019, National 
Cardiovascular Research Center, Osaka, Japan) and performed according to the Guide for the Care and Use of 
Laboratory Animals published by the U.S. National Institutes of Health (NIH publication 85-23, revised 1996)20 
and ARRIVE guidelines (https:// arriv eguid elines. org).
Radiopharmaceuticals. [18F]FDG was supplied from Nihon Medi-Physics Co., Ltd., Tokyo, Japan. Radio-
chemical purity was greater than 95% for radiolabelled compounds.
Cell preparation. Human MSCs from bone marrow were purchased from PromoCell GmbH (Heidelberg, 
Germany) and were cultured in Mesenchymal Stem Cell Growth Medium 2 (MSCGM2, PromoCell GmbH). 
Media was changed after 24 h to select for adherent cells and subsequently every 3 days until 80% confluence 
was reached. MSCs were cultivated and passaged as needed, never exceeding passage 5 for use in subsequent 
experiments.
[18F]FDG cell uptake and washout assay. [18F]FDG uptake study with MSCs was performed as previ-
ously  reported21 with a minor modification. In brief, cells (1.0–3.0 ×  106 cells/well in 6-well plate) were washed 
with Dulbecco’s phosphate-buffered saline (DPBS, Nacalai Tesque Inc., Kyoto, Japan). DPBS containing 4.5–5.5 
MBq/mL [18F]FDG was added to each well. After 60 min incubation (37 °C, 5%  CO2), the medium was removed 
and [18F]FDG uptake into the cells was immediately terminated by applying 2 ml of ice-cold DPBS. The cells 
were washed twice with 2 ml of ice-cold DPBS and then lysed with 0.1 M NaOH for 60 min for protein and radi-
oactivity measurements. The protein of each cell lysate was measured using a BCA Protein Assay Kit (Thermo 
Scientific™ Pierce™ BCA Protein Assay Kit, Thermo Fisher Scientific K.K., Tokyo, Japan) and iMark™ Microplate 
Absorbance Reader (Bio-Rad Laboratories, Inc., CA, USA). The radioactivity of each lysate was measured by a 
γ-counter (1480 WIZARD™ 3, PerkinElmer, Inc., MA, USA). For uptake kinetics assessment (n = 3), cells were 
incubated with [18F]FDG for different incubation times (5 min, 15 min, 30 min, 60 min and 120 min), with and 
without glucose in DPBS (2.0 mg/mL). For the assessment of radiotracer washout from the cells, after the 60 min 
cell labelling, the cells were kept in the DPBS (37 °C, 5%  CO2) not containing [18F]FDG for different time peri-
ods (60 min, 180 min and 360 min), then washed two times and the counts remaining in the cells were measured.
Cell preparation for in vivo animal study. For PET imaging, MSCs were incubated with DPBS contain-
ing 4.5–10.0 MBq/mL [18F]FDG for 60 min (37 °C, 5%  CO2) and resuspended in 1.0 mL of 37 °C pre-warmed 
DPBS after being washed three times with DPBS.
Animals. All animals fasted overnight with free access to water up to 1 h before anaesthesia. For in vivo 
experiments, male C57BL/6 mouse (n = 1, weighing 21 g, Charles River Laboratories JAPAN, Inc., Kanagawa, 
Japan), male Wistar rats (n = 13, 9–21 weeks, weighing 150–250 g, Japan SLC, Inc. Shizuoka, Japan), and male 
New Zealand white rabbits (3 y/o, weighing 3.8–4.1 kg, Japan SLC, Inc.) were used. General anesthesia was 
induced by using 5% isoflurane (ISOFLURANE Inhalation Solution; Pfizer Japan Inc., Tokyo, Japan) and was 
maintained during the experiment with 2% isoflurane. For experiments with non-human primates (NHPs) (5 
males and 1 female rhesus macaques, 3.5–4.5 y/o, weighing 3.3–5.3 kg, Primate Research Institute Kyoto Univer-
sity, Aichi, Japan) were used. Induction of anaesthesia in NHPs was conducted by intramuscular injection of ket-
amine (1.5 mg/kg) and xylazine (0.6 mg/kg) to allow preparation and handling of the animals. After a tracheal 
cannula was inserted, 1.5% sevoflurane (SEVOFLURANE Inhalation Solution; Pfizer Japan, Inc.) vaporized with 
100% oxygen was inhaled and the tidal volume and respiratory rate of the ventilator were monitored and kept 
in the normal range throughout the imaging sessions with an anaesthesia workstation (Apollo®, Drägerwerk 
AG & Co. KGaA. Lübeck, Germany). During the PET imaging session, animals were placed on the scanner bed 
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in a prone position for mouse, rats, and rabbits and a supine position for NHPs and safely attached to keep the 
position during the scan. The animals were covered with blankets or laying on the heating bed to maintain body 
temperature.
Cell administration in animal studies. In vivo studies are conducted using a mouse, rats, rabbits and 
NHPs with different route of MSC administration, and scanned at 10 min after the cell administration. Intrave-
nous administration of MSCs were performed via tail vein in the mouse (n = 1, 8.5 ×  104 cells, 0.1 mL) and rats 
(n = 4, 4.6–19.0 ×  105 cells, 1.0 mL), via ear vein in the rabbits (n = 4, 1.3–2.5 ×  107 cells, 1.0 mL), and via arm vein 
in the NHPs (n = 3, 1.2–2.2 ×  107 cells, 1.0 mL). Administration via carotid artery (common) was performed in 
rats (n = 4, 4.9–16.3 ×  105 cells, 1.0 mL) and NHPs (n = 3, 1.2–2.2 ×  107 cells, 1.0 mL). Intra-myocardial injection 
was performed in rats (n = 5, 1.3–1.6 ×  106 cells, 0.25 ml) using 27G needles under thoracotomy (Fig. 1).
PET imaging. PET scans of mouse and rats were obtained using a dedicated small-animal PET system 
(microPET FOCUS 120, Siemens Healthcare K.K., Tokyo, Japan), while a clinical PCA-2000A positron scan-
ner (Toshiba Medical Systems Corporation, Tochigi, Japan) was used for the scans of rabbits and NHPs. PET 
imaging was started 10 min after the injection of [18F]FDG–labelled MSCs. Whole-body PET acquisitions were 
obtained (total 30 min for one bed position for a mouse, total 90 min for three bed positions for rats, 30 min for 
3 bed positions for rabbits, and 40 min for 4 bed positions for NHPs). The data were sorted into 3-dimensional 
sinograms, which were then reconstructed with a Fourier transformation to produce dynamic images using 
a 2-dimensional ordered-subset expectation maximization (OSEM) algorithm. All images were corrected for 
fluorine-18 decay, random and dead time; correction for attenuation was not performed for mouse and rats, but 
attenuation correction was performed for rabbits and  NHPs22. The obtained PET images were analysed with the 
public domain tool AMIDE imaging software (A Medical Imaging Data Examiner, version 1.01, http:// amide. 
sourc eforge. net/).
Following the PET imaging session of rats, the hearts, lungs, and brains were harvested for analysis of tissue 
counts with a γ-counter (1480 WIZARD™ 3). Following decay correction of tissue counts, percent injected dose 
(%ID) = 100 × (radioactivity in organ)/[(activity injected)] in each organ was calculated.
Statistics. Results are given as mean ± SD. The two-tailed paired Student’s t-test was used to compare differ-
ences between dependent groups and the two-tailed independent Student’s t-test between independent groups. 
Multiple group comparisons were performed using analysis of variance (ANOVA) followed by Dunnett’s multi-
ple comparison test. A value of p less than 0.05 was considered statistically significant.
Ethical standards. All applicable international, national and/or institutional guidelines for the care and use 
of animals were followed. All experimental procedures using animals were approved by the Animal Ethics Com-
mittee of the National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan.
Results
[18F]FDG uptake and retention. [18F]FDG uptake in the MSCs was completely inhibited by adding 
glucose (2.0 mg/mL) in the buffer media (Fig. 2). The radiotracer activity (without decay correction) increased 
in a time dependent manner up to 60 min and plateaued at 120 min (Fig. 2), suggesting that optimal incubation 
time to achieve high fluorine-18 counts from the cells is approximately 60 min. [18F]FDG washout from the 
cells was observed when kept in the DPBS (Fig. 2). 80–90% of fluorine-18 radioactivity remained in the MSCs 
after 60 min, while more than 50% of the fluorine-18 signal was washed out from the cells into the media after 
180–360 min.
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PET imaging of [18F]FDG labelled MSCs after peripheral vein administration in different ani‑
mals. PET imaging in a mouse, rats, rabbits, and NHPs was successfully conducted after administration of 
[18F]FDG labelled MSCs. In all animal species, intense radiotracer signal was detected in the bilateral lung 
(Fig. 3), and slightly increased activity was seen in the urinary tract system. Percentage of [18F]FDG uptake 
(%ID) in rabbits estimated by the PET images were 59.2 ± 2.6, 6.4 ± 1.0* and 25.1 ± 0.6* for the lung, head, and 
abdomen area, respectively (*vs lung, p < 0.0001).
Different routes of cell administrations in rats and NHPs. After common carotid artery cell admin-
istration and intra-myocardial cell injection in rats, completely different radiotracer distribution patterns were 
seen in PET images (Fig. 4). Most of the radiotracer signal remained in the head area after carotid artery admin-
istration, while a strong signal remained in the heart after intra-myocardial injection. Minimal radiotracer activ-
ity in the lungs was detected after injection through either route, unlike peripheral vein administration which 
led to predominant lung signal. The results of the rat experiments were consistent with the results obtained after 
administration to NHPs via common carotid artery (Fig. 5). High radiotracer signal at the head area (side of 
tracer injection) was observed, while almost no lung activity was detected in PET images of all three NHPs that 
received the cells via carotid artery injection.




























































Figure 2.  In vitro [18F]FDG uptake kinetics in MSCs (left) and radiotracer washout from the cells (right). 
Radiotracer activity in the cells was plateaued at 60–120 min incubation (physiological fluorine-18 decay 
correction). Radiotracer signal remained in the cells at a level of approximately 80–90% after 60 min, while 
decreased by nearly 50% after 180 min.
Figure 3.  Representative whole body PET images after [18F]FDG labelled MSCs administration via peripheral 
vein in a mouse (A), rat (B), rabbit (C), and non-human primate (D). Images of the mouse and rat are fused 
with CT (gray scale) and rabbit and non-human primate are fused with transmission scan (gray scale). High 
radiotracer signal is seen in the lung of all tested animal species. Quantification of [18F]FDG distribution (%ID) 
in the lung, head, and abdomen area in rabbits (E).
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Discussion
In this study, we successfully visualized initial distribution of administrated MSCs in multiple animal species 
using a combination of highly sensitive PET imaging and simple in vitro cell pre-labelling with the glucose 
analogue [18F]FDG. Two different PET scanners, a high-resolution, small-animal and a large-bore-size clinical 
PET system, were employed to accommodate the differences in animal sizes from mouse to NHP. A typical small 
animal PET system has a gantry bore diameter of ~ 10–20 cm and available for small rodents such as mouse and 
 rat23, while a standard clinical PET system has a gantry bore opening ~ 60–80 cm which easily accommodates 
 NHPs24. To see the delicate anatomical structures in small animals, 1–2 mm of spatial resolution are achieved 
in small-animal scanner systems, while typically 3–4 mm of special resolution can be achieved in a clinical PET 
 system24,25.
Several different techniques that utilize radionuclides for visualization of transplanted cells have been pro-
posed that utilize  radionuclides26,27. There two methods that have been explored most extensively are direct 
pre-labeling and the reporter gene approach. As shown in the current study, direct pre-labeling of the cells 
prior to the administration is a straightforward manner in which to visualize the delivery of the administrated 
cells. Multiple different radionuclides have been tested, including commercially available [111In]In-oxine kits 
for clinical leukocyte inflammatory imaging. For the visualization of indium-111 radioactivity signal, a gamma 
camera system must be used, often in single-photon emission computed tomography (SPECT) mode. Although 
the higher accessibility is an advantage of the SPECT technology, PET has intrinsic advantages including better 
temporal and spatial resolution, higher sensitivity for detection of the radiotracer, and established algorithms 
for attenuation correction as well as absolute quantification of  distribution28. The radiotracer used to label the 
Figure 4.  Representative PET images of rats with cell administration via tail vein (A), common carotid 
artery (B), and intra-myocardial injection (C). High radiotracer activity is seen in the lung, head, and heart 
in the group of animals with tail vein administration, carotid artery injection, and intra-myocardial injection, 
respectively. Results of tissue counting of the lung (D), brain (E), and heart (F) with different routes of cell 
administration are shown in the graphs.
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cells in this study was [18F]FDG, which is an analogue of glucose and the most widely used PET agent in the 
clinical arena, making it easily  obtainable17,18. However, potential limitations of direct labeling cell imaging are 
the decay of the radioactivity and radiotracer leakage from the cells. In our in vitro washout assay, almost 50% of 
the radioactivity had diffused out of the cells at 180 min, and the radioisotope fluorine-18 decay half-life is 109.77 
min. Therefore, [18F]FDG labeled cell imaging may be limited to no later than 60 min after cell injection, making 
this method most suitable for the evaluation of initial cell distribution and the early phase of cell engraftment.
To overcome those limitations, reporter gene cell imaging has been  introduced29–31. In this approach, the 
donor cells need to be genetically modified to stably express a reporter protein that selectively takes up a specific 
radiotracer into the cells. Several pairs of reporter protein and reporter probe have been developed and tested 
in animal models, such as herpes simplex type 1 thymidine kinase (HSV1-sr39tk) as a reporter and 9-(4-[18F]
fluoro-3-hydroxymethylbutyl) guanine as a probe (31), and sodium/iodine cotransporter as a symporter and 
iodine-123/124/131 or technetium-99m as a  probe29,30. A key feature of reporter cell imaging is the possibility 
of monitoring cells over time. If the cells keep expressing the reporter protein after transplantation, repeated 
systemic administration of the radiotracer allows for longitudinal imaging of cell  localization30. Although the 
reporter gene approach has attractive features for cell imaging, several hurdles still need to be overcome including 
standardization of efficient and safe cell genetic labeling technology, as well as high physiological background 
tracer activity and low cell detection sensitivity as compared to direct cell labeling methods.
In this PET study, clear radiotracer signal in the bilateral lung fields were detected after intravenous human 
MSCs administration in all tested animal species, most likely indicating donor cell entrapment. The size of 
human MSCs is 15–50 μm in diameter with an average of 26.5 μm32, whereas the average pulmonary capillary 
diameter is ~ 12 µm in human and mouse, i.e. much smaller than the size of  MSCs33. Additionally, cell adhesion 
abilities are also suggested as a factor for the pulmonary cell trapping mechanism in  capillaries34. Different tracer 
distribution in rats and NHPs after MSCs administration via common carotid artery as compared to intravenous 
administration could also be explained by cell entrapment at the peripheral capillary. Moreover, we could also 
Figure 5.  All whole-body PET coronal images of non-human primates (n = 6) after administration of [18F]
FDG labeled MSCs via arm vein (n = 3, upper left) and common carotid artery (n = 3, upper right). PET images 
are fused with transmission scan images (gray scale). High activity in the bilateral lung is seen in the animals 
with cell injection via arm vein, while high activity in the head is seen in the animals injected via carotid 
artery. Quantitative PET signals in the lung (lower left) and the head area (lower right) with different cell 
administration routes are shown.
7
Vol.:(0123456789)
Scientific Reports |        (2021) 11:10896  | https://doi.org/10.1038/s41598-021-90383-4
www.nature.com/scientificreports/
observe high radiotracer accumulation in the head after carotid artery administration (Fig. 4B,E). In animals 
after focal brain injury, which have been injected with MSC into the carotid artery, MSCs were capable of hom-
ing to the perivascular  space35, thereby showing no migration to deeper brain areas. The latter compartment is 
crucially involved in the replacement of injured pericytes, which facilitates restoration of central nervous system 
 function36 after brain damage and is also tightly linked to  MSC37, potentially explaining why radiotracer signal 
also remained in the head area after carotid artery administration in our study. Moreover, in patients afflicted 
with heart failure, intramyocardial injection of MSC of individuals undergoing a left ventricular assist device 
implant did not lead to an increased rate of weaning from device support relative to patients without MSC 
injection into the  myocardium38. This was partially explained by an increased level of inflammation around the 
surgical intervention, potentially leading to increased death of MSC, e.g. by paracrine  signaling38. Of note, in 
our study enrolling healthy animals, increased radiotracer accumulation was observed after injection of MSC 
into the myocardium (Fig. 4C,F). Therefore, future studies should evaluate the potential of this administration 
route in animals after cardiac damage, e.g. post-myocardial infarction, in particular as PET can then reveal the 
retention capacities of the MSC in-vivo prior to any MSC-based therapeutic intervention.
The results of the present study obtained in different species may lay the foundation for future translational 
studies, e.g. to track the optimal number of transplanted cells or to assess cell viability and retention to increase 
efficacy of MSC-based treatments. Then, preclinical stem cell monitoring studies mimicking clinical situations 
such as animal model of diseases and different types of donor cells are warranted. These considerations are further 
fueled by the fact that clinical trials e.g. on cerebral infarction and chronic ischemic heart disease and stem cell 
therapy have yielded mixed  results39,40. Beyond cardiovascular disease, recent studies also demonstrated that 
transplanted MSCs are mainly trapped in the lung, e.g. in animal models of pulmonary emphysema mimicking 
cigarette  smokers41,42. This is in contradistinction to the brain, as MSC can cross the blood brain  barrier43. There-
fore, PET imaging of [18F]FDG-labeled stem cells may reveal retention capacities in the target organ (e.g. in the 
lung), but can also assess the off-target response of transplanted MSC (e.g. in the brain), ultimately identifying 
the optimal individual which will most likely benefit from treatment with almost no or negligible side  effects44–46.
Conclusions
Using a combination of dedicated small animal PET and clinical PET systems, [18F]FDG pre-labelled cells 
were visualized after different routes of cell administration in multiple animal models. Those results highlight 
the potential use of PET as a research platform for the understanding of in vivo cell kinetics and optimization 
of procedures for stem cell therapy.
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